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Background
The Muckle-Wells syndrome (MWS) is a rare inherited
disease and belongs to the group of cryopyrin-associated
periodic syndromes (CAPS). Recurrent fever attacks, myal-
gia, arthralgia, urticarial rash, headache, conjunctivitis, sen-
sorineural deafness and a severe fatigue syndrome are the
typical symptoms of MWS. Due to an unregulated produc-
tion of IL1 a continuous formation of serum amyloid leads
ultimately to the development of AA-amyloidosis, which is
life-threatening and in some cases the fatal complication of
MWS.
Objectives
The anti-IL1ß-monoclonal antibody canakinumab has
been introduced as a specific therapy in patient with
MWS with normal and impaired renal function. There are
no long term data about the effect from canakinumab in
patients with renal transplantation.
Methods
Here we report the five years follow up on a 36-year old
female patient with Muckle-Wells syndrome and biopsy
proven systemic AA amyloidosis and end stage renal dis-
ease. After renal transplantation therapy with canakinu-
mab subcutaneously in a dosage of 150 mg every eight
weeks was continued in combination with the immuno-
suppressive therapy.
Results
Before and after renal transplantation the patient had a
very good response to canakinumab with low activity in
inflammation markers with an improved quality of life.
Over the period of five years the triple immunosuppressive
therapy (CSA, MMF, Prednisone) in combination with
canakinumab has had no negative effect on activity of
MWS and no pharmacological interactions between medi-
cations were observed. Even five years after renal trans-
plantation, the patient remains an excellent kidney
function without proteinuria. There are no signs of recur-
rence of AA-amyloidosis in the transplanted kidney.
Conclusions
According to our data, treatment with different immu-
nomodulators in patients with Muckle-Wells syndrome
and renal transplantation is safe, feasible and without
severe side effects also over a longer time.
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